Anaplastic thyroid carcinoma, version 2.2015

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Andreas Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn & 10 others John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

Original languageEnglish (US)
Pages (from-to)1140-1150
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

docetaxel
Thyroid Neoplasms
Practice Guidelines
Doxorubicin
Cisplatin
Guidelines
Carcinoma
Therapeutics
Anaplastic Thyroid Carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., ... Hughes, M. (2015). Anaplastic thyroid carcinoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(9), 1140-1150. https://doi.org/10.6004/jnccn.2015.0139
Haddad, Robert I. ; Lydiatt, William M. ; Ball, Douglas W. ; Busaidy, Naifa Lamki ; Byrd, David ; Callender, Glenda ; Dickson, Paxton ; Duh, Quan Yang ; Ehya, Hormoz ; Haymart, Megan ; Hoh, Carl ; Hunt, Jason P. ; Iagaru, Andrei ; Kandeel, Fouad ; Kopp, Peter Andreas ; Lamonica, Dominick M. ; McCaffrey, Judith C. ; Moley, Jeffrey F. ; Parks, Lee ; Raeburn, Christopher D. ; Ridge, John A. ; Ringel, Matthew D. ; Scheri, Randall P. ; Shah, Jatin P. ; Smallridge, Robert C. ; Sturgeon, Cord ; Wang, Thomas N. ; Wirth, Lori J. ; Hoffmann, Karin G. ; Hughes, Miranda. / Anaplastic thyroid carcinoma, version 2.2015. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 9. pp. 1140-1150.
@article{c1873f683c25422e89c2045c417df881,
title = "Anaplastic thyroid carcinoma, version 2.2015",
abstract = "This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.",
author = "Haddad, {Robert I.} and Lydiatt, {William M.} and Ball, {Douglas W.} and Busaidy, {Naifa Lamki} and David Byrd and Glenda Callender and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Kopp, {Peter Andreas} and Lamonica, {Dominick M.} and McCaffrey, {Judith C.} and Moley, {Jeffrey F.} and Lee Parks and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Smallridge, {Robert C.} and Cord Sturgeon and Wang, {Thomas N.} and Wirth, {Lori J.} and Hoffmann, {Karin G.} and Miranda Hughes",
year = "2015",
month = "9",
day = "1",
doi = "10.6004/jnccn.2015.0139",
language = "English (US)",
volume = "13",
pages = "1140--1150",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

Haddad, RI, Lydiatt, WM, Ball, DW, Busaidy, NL, Byrd, D, Callender, G, Dickson, P, Duh, QY, Ehya, H, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, PA, Lamonica, DM, McCaffrey, JC, Moley, JF, Parks, L, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Smallridge, RC, Sturgeon, C, Wang, TN, Wirth, LJ, Hoffmann, KG & Hughes, M 2015, 'Anaplastic thyroid carcinoma, version 2.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 9, pp. 1140-1150. https://doi.org/10.6004/jnccn.2015.0139

Anaplastic thyroid carcinoma, version 2.2015. / Haddad, Robert I.; Lydiatt, William M.; Ball, Douglas W.; Busaidy, Naifa Lamki; Byrd, David; Callender, Glenda; Dickson, Paxton; Duh, Quan Yang; Ehya, Hormoz; Haymart, Megan; Hoh, Carl; Hunt, Jason P.; Iagaru, Andrei; Kandeel, Fouad; Kopp, Peter Andreas; Lamonica, Dominick M.; McCaffrey, Judith C.; Moley, Jeffrey F.; Parks, Lee; Raeburn, Christopher D.; Ridge, John A.; Ringel, Matthew D.; Scheri, Randall P.; Shah, Jatin P.; Smallridge, Robert C.; Sturgeon, Cord; Wang, Thomas N.; Wirth, Lori J.; Hoffmann, Karin G.; Hughes, Miranda.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 9, 01.09.2015, p. 1140-1150.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Anaplastic thyroid carcinoma, version 2.2015

AU - Haddad, Robert I.

AU - Lydiatt, William M.

AU - Ball, Douglas W.

AU - Busaidy, Naifa Lamki

AU - Byrd, David

AU - Callender, Glenda

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter Andreas

AU - Lamonica, Dominick M.

AU - McCaffrey, Judith C.

AU - Moley, Jeffrey F.

AU - Parks, Lee

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Smallridge, Robert C.

AU - Sturgeon, Cord

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Hoffmann, Karin G.

AU - Hughes, Miranda

PY - 2015/9/1

Y1 - 2015/9/1

N2 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

AB - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

UR - http://www.scopus.com/inward/record.url?scp=84941787533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941787533&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0139

DO - 10.6004/jnccn.2015.0139

M3 - Review article

VL - 13

SP - 1140

EP - 1150

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G et al. Anaplastic thyroid carcinoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 2015 Sep 1;13(9):1140-1150. https://doi.org/10.6004/jnccn.2015.0139